This is a dose escalation, non-randomized, open label, single site study of DS-8895a in patients with advanced or metastatic EphA2 positive cancers. Patients will receive an initial 89Zr trace labelled infusion of DS-8895a, followed by safety assessments, PET imaging and pharmacokinetic sampling over a one week period. DS-8895a will then be infused on Day 8, and second weekly infusions of DS-8895a, for a further two infusions, will subsequently occur. The day 36 infusion of DS-8895a will also be trace labelled with 89Zr, with subsequent PET imaging and pharmacokinetic sampling. Four dose levels (1, 3, 10 and 20mg/kg) will be evaluated, with 3-6 patients entered at each dose level. Those patients who respond or have stable disease on RECIST at Day 50 restaging may continue on biweekly treatment of DS-8895a until disease progression, with restaging CT scans every 6 weeks.